Acrivon adds oral JAK1 inhibitor ACR-525 as ACR-368 interim analysis nears
The US oncology biotech reported Q3 2026 results, reporting an immunology acquisition, early ACR-2316 data plans, and cash of $77.8 million expected to last into Q4 2027.
Acrivon Therapeutics reported its third-quarter 2026 results on 16 November, alongside news that it has acquired ACR-525, an oral JAK1 inhibitor that is ready to enter Phase 2 development. The company plans to target eosinophilic esophagitis first.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Acrivon Therapeutics, Inc. ↗
Article written by VigiEye from the official source (Acrivon Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.